|Mr. Naoyuki Mochida||Pres & Director||N/A||N/A||N/A|
|Mr. Yoichi Kono||Exec. MD & Director||N/A||N/A||N/A|
|Keiichi Sagisaka||Sr. Exec. MD & Director||N/A||N/A||N/A|
|Chu Sakata||Sr. Exec. MD & Director||N/A||N/A||N/A|
|Kiyoshi Mizuguchi||Exec. MD & Director||N/A||N/A||N/A|
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. It provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products. The company has collaboration with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Mochida Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.